Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Information for site staff

Every COVID-19 patient in the UK may be invited to participate in the RECOVERY Trial. Randomisation includes the following arms: usual care alone; REGN-COV2 monoclonal antibodies; aspirin, colchicine, baricitinib and dimethyl fumarate. The trial is designed to have the least possible impact on NHS staff. You will find Frequently Asked Questions on the site set-up page.

See Update Alerts on this page for update details.  

UK

Loading...

RECOVERY-website_icons_site-set-up-2 (003).png

RECOVERY-website_icons.png

RECOVERY-website_icons_SITE-TEAMS.png

RECOVERY-website_icons_training.png

RECOVERY-website_icon_randomisation.png

RECOVERY-website_icons_follow-up (003).png

update alert

5 March 2021

On the recommendation of the trial Data Monitoring Committee, colchicine has been removed from the RECOVERY trial randomisation. Further information is available on the news page and in a letter sent to investigators.

24 February 2021

Substantial amendment 16 has been implemented today. We will provide additional information about dimethyl fumarate shortly.

STUDY PROTOCOL

The RECOVERY Trial protocol is available for use by investigators everywhere to design their own randomised trials that could help identify effective treatments for COVID-19.

Study protocol